NASDAQ : ORMP
Oramed Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 175.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 170.97M |
| Enterprise Value | 99.22M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 41.60M |
| Shares Outstanding | 41.60M |
| Shares Change (YoY) | +2.31% |
| Shares Change (QoQ) | +1.27% |
| Owned by Insiders (%) | 22.25% |
| Owned by Institutions (%) | 34.87% |
| Float | 29.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 0.99 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 0.57 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.98 |
| Quick Ratio | 4.85 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 74.24% |
| Return on Assets (ROA) | -3.42% |
| Return on Invested Capital (ROIC) | -5.23% |
| Return on Capital Employed (ROCE) | -4.05% |
| Weighted Average Cost of Capital (WACC) | 11.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $43.52M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 45.41M |
| Effective Tax Rate | 20.62% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.28 |
| 52-Week Price Change | +73.42% |
| 50-Day Moving Average | 4.57 |
| 200-Day Moving Average | 4.03 |
| Relative Strength Index (RSI) | 39.20 |
| Average Volume (20 Days) | 121,566 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.45M |
| Short Previous Month | 1.43M |
| Short % of Shares Out | 3.49% |
| Short % of Float | 4.86% |
| Short Ratio (days to cover) | 8.61 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.52M |
| Pretax Income | 220.28M |
| Net Income | 174.06M |
| EBITDA | -14.40M |
| EBIT | -14.52M |
| Earnings Per Share (EPS) | $4.15 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 50.61M |
| Total Debt | 733,000 |
| Net Cash | 71.75M |
| Net Cash Per Share | $1.72 |
| Equity (Book Value) | 317.47M |
| Book Value Per Share | 7.68 |
| Working Capital | 42.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.21M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 122,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.22M |
| FCF Per Share | -$0.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.25 |
| Dividend Yield | 6.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.03% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.31% |
| Shareholder Yield | 3.78% |
| Earnings Yield | 100.92% |
| FCF Yield | -3.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.39 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |